Drug Type Induced pluripotent stem cells (iPSC), CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism T-cell surface glycoprotein CD5 inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Precursor B-lymphoblastic lymphoma/leukemia recurrent | Preclinical | Japan | 07 Dec 2024 | |
| Refractory Leukemia | Preclinical | Japan | 07 Dec 2024 | |
| T-cell lymphoma recurrent | Preclinical | Japan | 07 Dec 2024 | |
| T-cell lymphoma refractory | Preclinical | Japan | 07 Dec 2024 |





